Regulatory B cells are numerically but not functionally deficient in anti-neutrophil cytoplasm antibody-associated vasculitis

Rheumatology (Oxford). 2014 Sep;53(9):1693-703. doi: 10.1093/rheumatology/keu136. Epub 2014 Apr 11.

Abstract

Objectives: B cells are central to the pathology of ANCA-associated vasculitis (AAV), a disease characterized by autoantibodies and effectively treated by rituximab. In addition to promoting inflammation, a subset of B cells act to suppress harmful autoimmune responses (Breg). The balance of effector and regulatory B cell subsets in AAV is not known. This study was conducted to assess the relative frequency of these subsets during different states of disease activity.

Methods: B memory (Bmem), naive (Bnaive) and regulatory (Breg) subsets were defined by their relative expression of CD24 and CD38. Function was assessed by cytokine production and suppressive action on CD4(+) Th1 activation evaluated in a co-culture system.

Results: Compared with healthy controls, the frequency of Breg (CD24(hi)CD38(hi)) was significantly reduced during disease remission in both proteinase 3 (PR3)- and MPO-ANCA patients and during acute disease in PR3-ANCA patients, while the frequency of memory cells (CD24(hi)CD38(lo)) was reduced during active disease and restored during remission. Breg cell frequency showed a positive correlation, while Bmem had an inverse correlation with IL-10 production in vitro. B and T cell co-cultures revealed that memory and naive B cell subsets augmented Th1 activation in vitro, which was prevented by Breg, and this pattern did not differ between remission AAV patients and controls.

Conclusion: In remission there is a numerical, but not functional, deficiency in Breg and preservation of Bmem associated with reduced IL-10 production and increased Th1 activation in vitro. This imbalance may contribute to the high rate of relapse observed in AAV, especially in PR3-ANCA patients.

Keywords: ANCA-associated vasculitis; B lymphocyte subsets; B regulatory cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / drug therapy
  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / immunology*
  • Antibodies, Monoclonal, Murine-Derived / therapeutic use
  • B-Lymphocyte Subsets / immunology
  • B-Lymphocytes, Regulatory / immunology*
  • Case-Control Studies
  • Coculture Techniques
  • Female
  • Humans
  • Immune Tolerance / immunology
  • Immunophenotyping
  • Immunosuppressive Agents / therapeutic use
  • Interleukin-10 / biosynthesis
  • Lymphocyte Activation / immunology
  • Male
  • Middle Aged
  • Remission Induction
  • Rituximab
  • Th1 Cells / immunology
  • Tumor Necrosis Factor-alpha / biosynthesis

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • Immunosuppressive Agents
  • Tumor Necrosis Factor-alpha
  • Interleukin-10
  • Rituximab